Liraglutide
Saxenda / Victoza
- Peptide length
- 31 amino acids
Acylated peptide analog
Open the sources to check how the studies were done and what they can support.
A GLP-1 receptor agonist with regulated diabetes and weight-management products and randomized weight-management evidence.
- Family
- Incretin analog
- Research target
- GLP-1 receptor
- Molecular form
- Acylated peptide analog
What to know about the research
The SCALE trial studied a defined formulation, population and duration. Different liraglutide products have different labeled uses.
Check the exact compound
Confirm the peptide modification, acyl chain and finished formulation; shared GLP-1 activity does not imply equal pharmacokinetics.
What supports this entry?
The reference list is available. A statement-by-statement source check has not been completed for this entry.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
No study details have been extracted for this exact entry yet. This does not mean that no studies exist. Open the references and check the exact material.
How we prepare and correct these entries